Tuesday, November 4, 2025 11/4/2025

Spatially Resolved Dynamics of Molecular Pathology and Intercellular Interactions in Amytrophic Lateral Sclerosis

Award Number: R01NS116350
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/01/2020
PERIOD OF PERFORMANCE END DATE: 01/31/2025

Group Awards By:

View Award Description

Spatially Resolved Dynamics of Molecular Pathology and Intercellular Interactions in Amytrophic Lateral Sclerosis - Project Abstract Amyotrophic lateral sclerosis (ALS) is a devastating progressive neurodegenerative disease in which the loss of upper (primary motor cortex, M1) and lower (spinal cord, SC) motor neurons (MNs) ultimately leads to total paralysis. MN loss in ALS involves cell autonomous and non-cell autonomous activities in multiple cell types of the M1 and SC, the organization of which are well understood. However, there remain 4 major gaps in our knowledge: 1) How ALS-associated molecular pathology in the various cell types of the M1 relates to those in the SC; 2) How subpopulations of specific cell types are spatially arranged in these two regions; 3) How subpopulations of different cell types are organized in higher-order ensembles; and 4) How the coordinated behavior of these ensembles relates to disease-associated molecular pathology (e.g., pathognomonic inclusions). Towards addressing these questions, we propose to develop a spatially resolved multi-omics catalog of cellular subpopulations in the M1 and SC of patients with ALS and healthy controls. By using a combination of approaches to simultaneously map the spatial transcriptome and proteome of all interacting cellular subpopulations in these regions, our aim is to elucidate the origins and temporal dynamics of inter- and intra-cellular activities that may reveal novel diagnostic and therapeutic targets for ALS. Our overarching hypothesis is that ALS pathology stems from dysfunctional MN-glial interactions, and that this predictably differs in the M1 and SC in accordance with patient symptomatology. To address this hypothesis, we propose to use spatially resolved transcriptomic and proteomic measurements to study intact human postmortem tissue from patients stratified by clinical presentation (i.e., site of initial symptom presentation, bulbar or lower limb). We have previously implemented Spatial Transcriptomics on mouse and human SC to identify regional differences within subpopulations of various cell types that vary as a function of disease dynamics. Here, we propose to build upon our existing human study, and for the first time, develop a spatially resolved multi-omics dataset at scale and in the context of disease in matched human postmortem M1 and SC samples (Aim 1), to enable simultaneous exploration of upper and lower motor neurons in the context of intact tissue. These data will be directly tied to measures of ALS pathology (e.g., pathognomonic inclusions). To integrate and analyze relationships between data across modalities, we will develop a computational framework for harmonized analysis of multi-modal, multi- omic measures of ALS disease burden (Aim 2). Finally, we will implement highly multiplexed immuno-imaging to validate top gene candidates generated in Aim 1 at a single-cell level in situ (Aim 3). We expect to obtain an unmatched view of cellular interactions in the postmortem ALS M1 and SC, and to be able to directly link such interactions to features of ALS pathology in situ. This will allow us to identify dysregulated signaling that drives upper and lower motor neuron loss and associated symptoms in patients in ALS.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $526,777 )
2024	2024	NEW YORK GENOME CENTER, INC.	101 AVENUE OF THE AMERICAS FL 7	NEW YORK	NY	10013	NEW YORK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	5	1/25/2024	NON-COMPETING CONTINUATION	$488,763
2024	2024	NEW YORK GENOME CENTER, INC.	101 AVENUE OF THE AMERICAS FL 7	NEW YORK	NY	10013	NEW YORK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	002	5	5/3/2024	NON-COMPETING CONTINUATION	-$16,292
2024	2024	NEW YORK GENOME CENTER, INC.	101 AVENUE OF THE AMERICAS FL 7	NEW YORK	NY	10013	NEW YORK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	5	4/9/2024	NON-COMPETING CONTINUATION	$54,306
														Subtotal = $526,777

Issue Date FY: 2023 ( Subtotal = $556,942 )
2023	2023	NEW YORK GENOME CENTER, INC.	101 AVE OF THE AMERICAS FL 7	NEW YORK	NY	10013	NEW YORK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	4	1/30/2023	NON-COMPETING CONTINUATION	$556,942
														Subtotal = $556,942

Issue Date FY: 2022 ( Subtotal = $567,750 )
2022	2022	NEW YORK GENOME CENTER, INC.	101 AVE OF THE AMERICAS FL 7	NEW YORK	NY	10013	NEW YORK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	3	1/11/2022	NON-COMPETING CONTINUATION	$510,974
2022	2022	NEW YORK GENOME CENTER, INC.	101 AVE OF THE AMERICAS FL 7	NEW YORK	NY	10013	NEW YORK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	002	3	4/1/2022	NON-COMPETING CONTINUATION	$56,776
2022	2021	NEW YORK GENOME CENTER, INC.	101 AVE OF THE AMERICAS FL 7	NEW YORK	NY	10013	NEW YORK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	12/13/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $567,750

Issue Date FY: 2021 ( Subtotal = $576,665 )
2021	2021	NEW YORK GENOME CENTER, INC.	101 AVE OF THE AMERICAS	NEW YORK	NY	10013	NEW YORK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	2	1/18/2021	NON-COMPETING CONTINUATION	$57,667
2021	2021	NEW YORK GENOME CENTER, INC.	101 AVE OF THE AMERICAS	NEW YORK	NY	10013	NEW YORK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	12/28/2020	NON-COMPETING CONTINUATION	$518,998
														Subtotal = $576,665

Issue Date FY: 2020 ( Subtotal = $606,794 )
2020	2020	NEW YORK GENOME CENTER, INC.	101 AVE OF THE AMERICAS	NEW YORK	NY	10013	NEW YORK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	1/20/2020	NEW	$606,794
														Subtotal = $606,794

Grand Total All Awards = $2,834,928

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Spatially Resolved Dynamics of Molecular Pathology and Intercellular Interactions in Amytrophic Lateral Sclerosis

Award Number: R01NS116350

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/01/2020

PERIOD OF PERFORMANCE END DATE: 01/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer